Iterum Therapeutics is a biopharmaceutical company focused on developing innovative antibacterial therapies to combat serious infections caused by multidrug-resistant bacteria
The company harnesses its expertise in microbiology and drug development to advance its therapeutic candidates through clinical trials, aiming to provide effective treatment options for patients with limited choices due to rising antibiotic resistance. With a commitment to addressing urgent public health challenges, Iterum Therapeutics is dedicated to delivering next-generation antibiotics that can improve patient outcomes and enhance global health.
Iterum Therapeutics' Orlynvah receives FDA approval for treating uncomplicated UTIs in adult women, marking its first approved indication and a U.S. first for oral penems.
Companies Reporting Before The Bell • Universal Stainless (NASDAQUSAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million.
Iterum Therapeutics announced positive topline results from its REASSURE (REnewed ASsessment of Sulopenem in uUTI caused by Resistant Enterobacterales) Phase 3 clinical trial comparing oral sulopenem (sulopenem etzadroxil combined with probenecid in a bilayer tablet) to oral Augmentin.
The Dow Jones index closed higher by over 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Companies Reporting Before The Bell • Consolidated Water Co (NASDAQCWCO) is estimated to report quarterly earnings at $0.22 per share on revenue of $30.27 million.
